STEMTECH CORP - STEK STOCK NEWS

Stemtech (STEK) has announced its uplisting to OTCQB, marking a significant milestone in its commitment to transparency and investor confidence. As a pioneer in stem cell nutrition, Stemtech is expanding its global footprint across the United States, Mexico, Ecuador, Canada, and Taiwan. The company offers innovative products in stem cell nutrition, skin care, oral care, and recently announced pet care technologies.

The global stem cells market is projected to grow from $14.92 billion in 2023 to $49.26 billion by 2034, with a CAGR of 11.47%. Stemtech's CEO, Charles S. Arnold, emphasizes the increasing awareness of stem cell benefits and the company's reasonably priced, life-maintenance system. With decades of research, Stemtech focuses on developing all-natural, plant-based stem cell products to enhance human and pet health, offering both health solutions and income-earning opportunities.

Stemtech (OTCQB:STEK) has launched StemPets™, a new product line for the $303 billion pet health care market. This natural stemceutical product, designed for dogs, cats, and other pets, aims to provide health benefits similar to Stemtech's human products. StemPets contains cashew nut-shell oil (Anacardic Acid) and a special stem cell nutrition formula to support organ repair, immune system, and joint health.

The product is non-GMO, free from artificial additives, and increases circulating stem cells in pets. Stemtech has secured an exclusive distribution agreement for StemPets. This expansion is expected to attract younger distributors, particularly Gen X individuals under 40. Stemtech has a history of delivering over $600 million worth of nutraceutical products with a return rate of less than 2%.

Stemtech (OTC Pink:STEK) CEO Charles S. Arnold addressed shareholders and Independent Business Partners regarding delays in SEC filings. The delays were attributed to an undisclosed asset acquisition and challenges with a new audit team unfamiliar with Stemtech's complex international business model. Despite being a $5 million revenue company, Stemtech's global presence required significant resources to meet auditors' requests.

The company's primary product, the RCM combination, has generated approximately $600 million in revenue with a low 2% return rate. Stemtech operates in the stem cell nutrition market, projected to reach $30 billion by 2030. The company is currently facing inventory challenges due to high product demand and is working on solutions to improve inventory levels.

Stemtech is making significant strides towards achieving its CEO and Chairman's goal of becoming cash flow positive. The company is focusing on revenue growth in existing countries and expanding into new markets, experiencing success with growth in revenue, new product offerings, and expansion into African and Western European countries. Stemtech's recognition in the top 5% of direct selling companies by 'Business for Home' underlines its position as a key player in the industry. The company's leadership emphasizes the growing demand for its products and the need for capital to support its expanding business.

Stemtech (STEK) announces the appointment of Mr. Darryl Green to lead their Rebranding Project, aiming to enhance their digital presence and market position. Mr. Green, a branding and nutraceutical specialist, brings extensive experience from his role as President of GNC's Global Franchising Division. Stemtech anticipates significant growth and success under his guidance.

Stemtech (STEK) experiences significant market growth due to high demand for its innovative stem cell-based nutraceuticals. The company's products, like Stemceuticals™, utilize the body's own stem cells for anti-aging and body repair. Stemtech expands its market reach to new African and European countries, leading to increased sales. The company faces inventory challenges due to overwhelming demand, prompting exploration of Raw Materials financing. Stemtech's President emphasizes the growing consumer interest in stem cell products and the company's commitment to meeting demand. The global stem cell and nutraceutical markets are projected to see substantial growth in the coming years.

Stemtech Corporation, a leader in stem cell nutrition, invites entrepreneurs to explore business opportunities through exclusive events. Their patented plant-based products support anti-aging and overall wellness without surgery. Join to learn more!

Stemtech Corporation (STEK) has secured an exclusive agreement with a direct sales company in Kenya to expand its patented stem cell nutrition products across six African nations. The agreement, effective January 29th, 2024, allows the purchase, use, marketing, and distribution of Stemtech's health-related products in Kenya, Uganda, Tanzania, Ghana, Democratic Republic of Congo, and Nigeria. This move demonstrates Stemtech's dedication to entering new markets and introducing its innovative products to a wider audience.

Stemtech Corporation (OTCQB:STEK) announces re-entry into the Colombian market and planned product line expansion in Ecuador. Stemtech generated over $10 million and had 3,000 IBPs in Colombia before the reorganization. Exciting pre-registration opportunity for IBPs in Colombia and Ecuador. Stemtech's self-sustained growth model and celebration of top producers highlight the company's commitment to international growth and community well-being.